FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

SALT LAKE CITY, June 14, 2021 -- (Healthcare Sales & Marketing Network) -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration (&... Biopharmaceuticals, FDA Lipocine, postpartum depression
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news